Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2049 | ISIS 721744 Wiki | 0.58 |
| drug3574 | Randomized to Umbilical Cord Milking at birth Wiki | 0.58 |
| drug3029 | PET-CT of 18F-FDG Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009421 | Nervous System Malformations NIH | 0.58 |
| D047928 | Premature Birth NIH | 0.26 |
| D001927 | Brain Diseases NIH | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000707 | Abnormality of the nervous system HPO | 0.58 |
| HP:0001622 | Premature birth HPO | 0.26 |
| HP:0001298 | Encephalopathy HPO | 0.24 |
Navigate: Correlations HPO
There are 3 clinical trials
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Description: Bayley Scales of Infant Development (BSID), 3rd or 4th Ed. Composite Score (cognitive 55-145, language 45-155, motor 45-155; higher scores are better)
Measure: Developmental Outcome Time: 22-26 months corrected gestational age (CGA). All assessments may be extended to 42 months CGA due to Covid-19 pandemic.Description: Defined having at least one of the following: a cognitive score <70, GMFCS greater or equal 2, blindness (vision <20/200), or hearing impairment interfering with the ability to communicate with amplification.
Measure: Moderate/Severe Neurodevelopmental Impairment Time: 22-26 months corrected gestational ageDescription: Defined having at least one of the following: a cognitive score 70-84, GMFCS =1, unilateral blindness (vision <20/200 in only one eye), or hearing impairment which does not interfere with the ability to communicate.
Measure: Mild Neurodevelopmental Impairment Time: 22-26 months corrected gestational ageDescription: The GMFCS is a validated system used to describe the severity of motor dysfunction. Scale measured from Level 0-5 with Level 0 being normal and Level 5 being the worst score. Measures ability to walk, sit, head control, voluntary movements and postures.
Measure: Gross Motor Function Classification System Scale (GMFCS) Time: 22-26 months corrected gestational ageDescription: Classified as None, Mild, Moderate or Severe based on GMFCS score; No CP = GMFCS Level 0, Mild CP = GMFCS Level 1, Moderate CP = GMFCS Levels 2-3, Severe CP = GMFCS Levels 4-5
Measure: Cerebral Palsy (CP) Time: 22-26 months corrected gestational ageDescription: Each domain is scored from 0 to 60, the higher score is better.
Measure: Developmental Outcomes assessed by Ages & Stages Questionnaire, 3rd ed. (ASQ-3) five domains: Communication, Gross motor, Fine motor, Problem solving and Personal-social in infants born between 23-32+6 weeks GA who received UCM or DCC. Time: 22-26 months corrected gestational ageDescription: BSID Cognitive, Language & Motor composite scores (cognitive 55-145, language 45-155, motor 45-155; higher scores are better) in infants 23-27 weeks GA and 28-32+6 weeks GA.
Measure: Developmental Outcomes in infants born at 23 -27 and 28-32 weeks GA who received UCM or DCC Time: 22-26 months corrected gestational ageDescription: ASQ-3 scores (0 to 60, the higher score is better) in infants 23-27 weeks GA and 28-32+6 weeks GA.
Measure: Developmental Outcomes in infants born at 23 -27 and 28-32 weeks GA who received UCM or DCC Time: 22-26 months corrected gestational ageDescription: Mild, moderate or severe impairment
Measure: Compare levels of developmental impairment as assessed by BSID-3 or 4 versus the ASQ-3 screening tool. Time: 22-26 months corrected gestational ageDescription: Any IVH grade from 1 to grade 4, higher grade is worse
Measure: Any grade intraventricular hemorrhage (IVH) in premature newborns 23 - 32+6 weeks GA who received UCM or DCC by mode of delivery (C-Section vs vaginal delivery) Time: From birth through hospital discharge, up to 6 months corrected gestational age (CGA)Description: Death
Measure: Death in premature newborns 23 - 32+6 weeks GA who received UCM or DCC by mode of delivery (C-Section vs vaginal delivery) Time: From birth through hospital discharge, up to 6 months corrected gestational age (CGA)Description: BSID Cognitive, Language & Motor composite scores (cognitive 55-145, language 45-155, motor 45-155; higher scores are better)
Measure: Compare neurodevelopmental outcomes from BSID assessments in newborns 23-32 weeks GA delivered by C-Section with those born by vaginal delivery receiving UCM or DCC. Time: 22-26 months corrected gestational ageDescription: ASQ-3 scores (0 to 60, the higher score is better).
Measure: Compare neurodevelopmental outcomes from ASQ assessments in newborns 23-32 weeks GA delivered by C-Section with those born by vaginal delivery receiving UCM or DCC. Time: 22-26 months corrected gestational ageDescription: Any grade IVH, from 1 to 4 (higher is worse)
Measure: Exploratory, hypothesis-generating Time: From birth through hospital discharge, up to 6 months corrected gestational age (CGA)Description: Hemoglobin or Hematocrit at 4 hours of age
Measure: Exploratory, hypothesis-generating Time: 4 hours of life +/- 2 hoursDescription: Delivery room interventions received: positive pressure ventilation, continuous positive airway pressure, intubation, chest compressions and medications
Measure: Exploratory, hypothesis-generating Time: In the first 10 minutes of lifeDescription: Blood pressures in the first 24 hours of life: on admission, 6, 12, 18 and 24 hours of life
Measure: Exploratory, hypothesis-generating Time: In the first 24 hours of lifeCT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.
Description: Visual analysis of the pulmonary lobes by calculating a extent score for each patient
Measure: Visual analysis of pulmonary lobes Time: 1 dayDescription: Measurement of metabolic activity with SUV max of lung areas with CT abnormalities
Measure: Measurement of metabolic activity Time: 1 dayThe SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.
Description: Plasminogen activator inhibitor-1 (PAI-1), E-selectin and angiopoietin-2
Measure: Dosage of biomarkers typically explored in intensive care unit delirium Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: S100 β, Neuron Specific Enolase (NSE), GFAP, UCHL1, NFL
Measure: Dosage of neuronal injury markers Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every 2 daysDescription: CAM-ICU (Confusion Assessment Method - Intensive Care Unit) scale
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: ICDSC (Intensive Care Delirium Screening Checklist) scale.
Measure: Delirium assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CRS-R (Coma Recovery Scale-Revised)
Measure: Coma assessment Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Clinical observation
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Pupilometer assessment
Measure: Pupils characteristics Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: Electroencephalogram : epileptic activity (spikes, spike-waves) or encephalopathy activity (triphasic waves))
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: CT-scan
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysDescription: MRI
Measure: Neurological abnormalities Time: Change from Day 0 (= First day in ICU) until the end of the stay (up to 3 months) - Assessments every daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports